Understanding Crohn’s Disease Infusion Therapy: What to Expect

Biologic infusions for Crohn’s disease are delivered either intravenously (IV) or subcutaneously and usually take 30 minutes to 4 hours. They are considered when standard oral or injectable medications fail to control inflammation.

Infusion therapy aims to induce deep remission by targeting specific pathways in the immune response. Because biologics suppress parts of the immune system, your doctor will confirm that you are otherwise healthy enough to tolerate potential side effects.

Most infusion products approved by the U.S. Food and Drug Administration (FDA) are derived from living cells and are designed to neutralize the inflammatory cascade that drives Crohn’s symptoms.

Infliximab (Remicade, Renflexis, Avsola) and Biosimilar IXIFI (infliximab‑qbtx)

Infliximab is an anti‑tumor necrosis factor (TNF) antibody. It binds to TNF‑α, a protein that fuels intestinal inflammation and can contribute to fistula formation. The biosimilar IXIFI works in the same manner.

Typical dosing: 5 mg/kg body weight (some patients receive 10 mg/kg). The induction schedule includes infusions at week 0, week 2, and week 6, followed by maintenance every 8 weeks (adjustable to every 4–6 weeks based on response).

Vedolizumab (Entyvio)

Vedolizumab is an anti‑integrin that blocks gut‑specific lymphocyte trafficking. It is often chosen after anti‑TNF therapy has failed.

Standard dose: 300 mg IV. Infusion schedule mirrors infliximab—induction at weeks 0, 2, 6, then maintenance every 8 weeks (or every 4 weeks if disease activity warrants).

Natalizumab (Tysabri)

Natalizumab inhibits the α4‑integrin receptor, reducing inflammatory cell migration. It is reserved for patients who do not respond to anti‑TNF agents.

Usual dose: 300 mg IV every 4 weeks. Clinical improvement may take up to 12 weeks (three infusion cycles). Monitor closely for neuro‑psychiatric effects, including depression.

Ustekinumab (Stelara)

Ustekinumab targets interleukins‑12 and ‑23, offering a distinct mechanism from other biologics.

Initial administration is a weight‑based IV infusion (approximately 1 hour). Subsequent maintenance is achieved with subcutaneous self‑injections every 8 weeks. Dosing is individualized based on body weight.

Before any infusion, clinicians screen for hepatitis B/C and latent tuberculosis, per FDA guidance.

During the infusion you will remain seated or reclined while a healthcare professional inserts an IV line. Observation after the first infusion is standard to detect acute reactions.

Infusion‑related adverse events differ from oral therapies and may include:

• Infections (due to immune suppression)
• Transient liver‑function abnormalities
• Joint pain (rare with anti‑TNF agents)
• Lupus‑like syndromes (rash, muscle aches, arthralgia)

Because biologic infusions are powerful disease‑modifying agents, they are prescribed only after other treatments have proven insufficient. When appropriately selected, they can dramatically slow disease progression and improve quality of life.